Cat. No. | Product name | CAS No. |
DC11825 |
MK-8876
A novel, broadly acting non-nucleoside inhibitor of HCV NS5B polymerase with IC50 of 3 nM and 2 nM for GT1b and GT2a, respectively. |
1426960-33-9 |
DC22790 |
MELK-T1 hydrochloride
A novel, cell-permeable, potent and selective inhibitor of MELK kinase domain with IC50 of 37 nM. |
1610536-69-0 |
DC23430 |
THRX-200495
A novel, dual-acting muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) with pKi of 9.21/9.53 for hM2/M3, pKi of 9.37 for β2-adrenoceptor. |
1442690-58-5 |
DC23454 |
V0162
A novel, high affinity and long-acting antagonist of human M3 muscarinic acetylcholine receptor with pKi of 9.03-9.21. |
147780-50-5 |
DC22756 |
CHF6001
A novel, highly potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 0.026 nM. |
1239278-59-1 |
DC24013 |
MUT-056399
A novel, highly potent inhibitor of the FabI enzyme of both Staphylococcus aureus and Escherichia coli. |
1269055-85-7 |
DC11676 |
NS15370
Featured
A novel, highly potent positive modulator of Kv7 channels with EC50 of 100 nM (Kv7.2-Kv7.5). |
2729996-51-2 |
DC21389 |
NKTR-181
A novel, long-acting and orally active, selective mu-opioid agonist that displays higher binding affinity (Ki=237 nM) at the MOR than kappa and delta opioid receptors (>100-fold). |
1211231-76-3 |
DC12011 |
KU-32
A novel, novobiocin-based, C-terminal inhibitor of Hsp90 and a potent inducer of Hsp70. |
956498-70-7 |
DC24094 |
Dofequidar
A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR. |
129716-58-1 |
DC22599 |
GLPG-0492
A novel, orally active, non-steroidal selective androgen receptor modulator (SARM) with in vitro potency of 13 nM. |
1215085-92-9 |
DC21542 |
PTC-596
A novel, orally active, small molecule inhibitor of BMI-1 that accelerates BMI-1 degradation, inhibits AML cells growth with IC50 of <100 nM. |
|
DC22981 |
A-37
A novel, potent and selective ALDH1A1 inhibitor with Ki of 300 nM and IC50 of 4.6 uM. |
896795-60-1 |
DC11799 |
G1T38
A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
1628256-23-4 |
DC11800 |
G1T38 dihydrochloride
A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. |
2097938-59-3 |
DC11804 |
IQS-019
A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively. |
1630804-24-8 |
DC11805 |
IQS-019 mesylate
A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively. |
1630804-27-1 |
DC20680 |
AS1604498
A novel, potent nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with IC50 of 44 nM. |
361465-74-9 |
DC22533 |
Eleclazine hydrochloride
Featured
A novel, potent, and selective inhibitor of Late sodium current (late INa) for treatment of long QT-3 syndrome (LQT-3), hypertrophic cardiomyopathy (HCM), and ventricular tachycardia–ventricular fibrillation (VT–VF). |
1448754-43-5 |
DC11938 |
IPI-3063
A novel, potent, and selective p110δ PI3K inhibitor with IC50 of 0.1 nM in cell-based assays. |
1425043-73-7 |
DC26067 |
BI1002494 trifluoroacetate
A novel, potent, and selective spleen tyrosine kinase (SYK) inhibitor with enzyme IC50 of 30 nM, cell IC50 of 7 nM (FcεR1-mediated histamine release in human monocyte-derived mast cells, in the presence of 0.1% albumin). |
1319738-41-4 |
DC11778 |
PKC-IN-6c
A novel, potent, brain permeant PKC inhibitor with IC50 of 80 nM, without detectable binding to the estrogen receptor (Ki>10 uM). |
2026603-86-9 |